Marisa Wexler, MS,  senior science writer—

Eli Lilly’s donanemab was found to work better than Aduhelm (aducanumab) in a biomarker study of people with early Alzheimer’s in removing disease-associated toxic protein clumps in the brain. The experimental therapy outperformed the approved treatment, from Eisai and Biogen, in a Phase 3 clinical trial, according…

Treatment with the experimental therapy BIIB080 led to long-term reductions in the levels of disease-associated tau protein in the brains of people with early Alzheimer’s disease. That’s according to new data from a Phase 1b trial (NCT03186989) presented by Biogen at the International Conference on Alzheimer’s and Parkinson’s…

Alzamend Neuro has completed the clinical portion of a Phase 2 trial testing AL001, an investigational formulation of lithium that the company is developing to treat Alzheimer’s disease and other disorders. Data from the trial now will be collected and analyzed. Top-line results are expected by this summer,…

The U.S. Food and Drug Administration (FDA) has agreed to review a request to convert Leqembi’s (lecanemab) accelerated approval to a traditional approval for treating Alzheimer’s disease. The FDA has granted priority review to the supplemental biologics license application (sBLA) and the agency is expected to make a…

The U.S. Food and Drug Administration (FDA) will consider brexpiprazole to treat agitation in people with Alzheimer’s disease. The supplementary new drug application, submitted by developers Otsuka Pharmaceutical and Lundbeck, has been granted priority review by the FDA, shorting its review time from the standard 10 months…

Treatment with lecanemab (BAN2401), an experimental amyloid-targeting antibody, significantly slowed the progression of dementia symptoms among people with early Alzheimer’s disease in the Phase 3 Clarity AD clinical trial, Biogen and Eisai announced. Both companies, the therapy’s developers, plan to discuss these results with regulatory authorities in the U.S.,…

Trametinib, an oral medication approved to treat certain cancers, improved cognition and neuronal health in a mouse model of Alzheimer’s disease, according to a new study. Data suggest the treatment helped to clear toxic protein aggregates from nerve cells. The study, “MEK1/2 inhibition rescues neurodegeneration by TFEB-mediated activation…

The U.S. Food and Drug Administration (FDA) has agreed to review an application from Eisai seeking accelerated approval of lecanemab (BAN2401), an investigational amyloid-targeting antibody to treat early Alzheimer’s disease in people with confirmed amyloid plaques in the brain. Eisai finished the rolling application a few months ago.

Hoth Therapeutics and Washington University have agreed to extend preclinical research into HT-ALZ, Hoth’s experimental therapy for Alzheimer’s disease. Research findings are expected to be helpful in estimating the best dose of HT-ALZ to test in potential clinical trials, according to a company press release. Hoth entered into…

Alzheimer’s patients given the experimental tau-targeting therapy HMTM in a Phase 3 clinical trial experienced a substantially slower decline in cognitive and functional measures than would be expected based on published research, according to new findings announced by HMTM’s developer TauRx Pharmaceuticals. TauRx expects these results will…